Investigational BTK Inhibitor Shows Efficacy in Chronic Spontaneous Urticaria

(MedPage Today) -- Remibrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, was safe and efficacious in patients with chronic spontaneous urticaria (CSU), a phase IIb extension study showed. In nearly 200 patients who received...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news